5 Deaths During Drug Trial

More than a year after five leukemia patients died from an experimental treatment involving genetically engineered immune cells, its developer believes it has a better handle on what went wrong—and possibly how to prevent a repeat of the tragedy. Juno Therapeutics, based in Seattle, Washington, last week presented the most comprehensive public results so far from its internal investigation, concluding that individual patient characteristics and “product variability” made for a lethal combination that led to fatal brain swelling. The company says it is now using insights from its analysis to inform work on a modified cell treatment that is in early-stage clinical trials.   

Read the article in it's entirety on Science : http://www.sciencemag.org/news/2017/11/cancer-immunotherapy-company-tries-explain-deaths-recent-trial